![]() ![]() Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. In Latin America, Moderna has established bilateral and supranational supply agreements in 15 countries. In 2021, 807 million doses of Moderna’s COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets. Regulators have approved Moderna’s COVID-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In addition, Moderna announced an agreement with Gavi, the Vaccine Alliance, to supply up to 650 million doses of the Company’s COVID-19 Vaccine across 20, covering the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. The Company also has commercial agreements with distributors to supply the Company’s COVID-19 vaccine in 45 countries, with Zuellig Pharma in the Asia Pacific, Medison Pharma in Central Eastern Europe and Israel, and Adium Pharma in Latin America. Moderna has a commercial presence in 11 countries worldwide (Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, UK, U.S.) and recently announced plans to increase its commercial footprint across ten additional markets in Asia-Pacific (Hong Kong, Malaysia, Singapore, Taiwan) and Europe (Belgium, Denmark, the Netherlands, Norway, Poland, Sweden) in 2022. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against COVID-19 and future vaccine-preventable diseases.” “A presence in Latin America is a key part of our global commercial strategy. ![]() “Our new partnership with Adium will help ensure broad access and delivery of our Moderna COVID-19 vaccine to people across Latin America,” said Stéphane Bancel, Chief Executive Officer of Moderna. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina. The team excels at complex cross-border transactions involving Bermuda, British Virgin Islands, Cayman Islands, Cyprus and Luxembourg vehicles.Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced a distribution service agreement with Adium Pharma S.A., a leading private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The team of corporate and finance lawyers at Harneys have strong networks with industry players and service providers in key markets around the world and understand the business environment in which their clients operate. The Adium group operates one of the leading pharmaceutical businesses in Latin America, with presence in 17 countries across the region and a track record of over 40 years, dedicated to the manufacturing, packaging, distribution, and commercialization of pharmaceutical products. Mitrani, Caballero & Ruiz Moreno acted as instructing law firm. The Harneys team was led by Partner Josh Mangeot, with support from Associate Ed Lacey. by a consortium of lenders, including Banco Itaú Uruguay S.A., which also acted as sole lead arranger and book runner. ![]() in relation to the US$130 million term loan financing of its subsidiary Adium Pharma S.A. Harneys acted as BVI counsel to Adium Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |